Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,841 companies covered, latest filing Oct 23.

  • $29.6B bought by 1412 insiders at 808 companies
  • $28.4B sold by 2631 insiders outside a trading plan
  • $21.2B sold by 1968 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past 3 months, each insider's filings added up.

  1. REBNReborn Coffee
    Jung Jae LimCEO
    131,387 shares at $180,000.00 Jul 14 New stake
    $23.6B
  2. RSGRepublic Services
    Cascade Investment, L.l.c.10% owner, +1 joint filer
    6,254,462 shares at $220.69 Aug 10–Sep 11, 12 filings +5.6% to stake
    $1.4B
  3. NMMNavios Maritime Partners
    Angeliki FrangouSee Remarks
    15,333 shares at $55,256.14 Jul 23–Aug 12, 5 filings +0.3% to stake
    $847M
  4. LENLennar
    Berkshire Hathaway Inc.10% owner, +1 joint filer
    7,502,276 shares at $79.35 Sep 17–Oct 2, 4 filings 3 superinvestors bought in Q2
    $595M
  5. JEFJefferies
    Sumitomo Mitsui Financial Group, Inc.Director
    5,906,542 shares at $54.86 Jul 15 +222% to stake 1 superinvestor bought in Q2
    $324M
  6. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    8,431,139 shares at $34.32 Sep 9–Oct 21, 30 filings +6.9% to stake 2 superinvestors bought in Q2
    $289M
  7. MAIRMadison Air Solutions
    Ernesto Bertarelli10% owner, +1 joint filer
    8,770,524 shares at $24.97 Aug 25 +23% to stake
    $219M
  8. GPIGroup 1 Automotive
    Conifer Management, L.L.C.10% owner
    720,030 shares at $260.08 Sep 1–30, 6 filings +60% to stake 2 superinvestors bought in Q2
    $187M
  9. KODKodiak Sciences
    Baker Bros. Advisors LPDirector, +5 joint filers
    1,941,755 shares at $80.85 Sep 28–29, 3 filings +11% to stake 1 superinvestor sold in Q2
    $157M
  10. SAFXXCF Global
    EEME Energy SPV I, LLC10% owner
    119M shares at $1.19 Oct 16 +109% to stake
    $142M

Biggest sales

Past 3 months, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    183,400 shares at $42,790.60 Aug 21–Oct 20, 6 filings Planned sale (10b5-1)
    $7.8B
  2. FANGDiamondback Energy
    SGF FANG Holdings, LP10% owner, +1 joint filer
    18.2M shares at $205.26 Sep 16, 2 filings 22% of stake
    $3.7B
  3. MDLNMedline
    GIC Private Ltd10% owner, +2 joint filers
    32.9M shares at $35.06 Aug 5–Oct 8, 5 filings
    $1.2B
  4. BIRKBirkenstock
    James Michael ChuDirector
    28.1M shares at $39.18 Aug 17 28% of stake
    $1.1B
  5. CHYMChime Financial
    DST Global Advisors Ltd10% owner, +9 joint filers
    32.5M shares at $32.93 Aug 6–Sep 14, 20 filings 99% of stake
    $1.1B
  6. NVDANvidia
    Mark A StevensDirector
    4,236,740 shares at $223.43 Aug 31–Sep 18, 3 filings 81% of stake
    $947M
  7. JMKEJersey Mike's Subs
    Submarine Buyer LLC10% owner, +6 joint filers
    32.3M shares at $21.85 Jul 31–Aug 25, 2 filings 15% of stake
    $705M
  8. AURAurora Innovation
    Uber Technologies, Inc10% owner
    101M shares at $6.45 Aug 17–Sep 15, 2 filings 39% of stake
    $654M
  9. ALHAlliance Laundry
    Bdt Capital Partners, LLCDirector, +6 joint filers
    25.9M shares at $22.74 Aug 20 18% of stake
    $590M
  10. ANETArista Networks
    Jayshree UllalCEO
    2,465,344 shares at $206.71 Aug 5–Oct 9, 9 filings Planned sale (10b5-1)
    $510M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 6 insiders, $1.7M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more

    Latest buy Oct 23 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Joel L. Frank Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

HOWL insider trades

Every open-market buy and sale in HOWL, one row per filing, newest first

HOWL page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $45K 143,199 shares at $0.3100 100% of stake
    Traded Jul 6–7 Filed Jul 8
    ↗
  2. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $47K 157,084 shares at $0.3000 52% of stake
    Traded Jun 29 Filed Jun 29
    ↗
  3. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $28K 76,928 shares at $0.3700 20% of stake
    Traded Jun 9 Filed Jun 10
    ↗
  4. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $43K 105,565 shares at $0.4100 22% of stake
    Traded Jun 4–8 Filed Jun 8
    ↗
  5. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $64K 139,803 shares at $0.4600 23% of stake
    Traded Jun 1–3 Filed Jun 3
    ↗
  6. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $66K 141,106 shares at $0.4700 19% of stake
    Traded May 27–29 Filed May 29
    ↗
  7. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $87K 191,762 shares at $0.4500 20% of stake
    Traded May 21–26 Filed May 26
    ↗
  8. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $76K 171,049 shares at $0.4500 15% of stake
    Traded May 18–20 Filed May 20
    ↗
  9. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $24K 44,679 shares at $0.5400 3.8% of stake
    Traded May 13 Filed May 13
    ↗
  10. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $280K 407,574 shares at $0.6900 26% of stake
    Traded May 8–12 Filed May 12
    ↗
  11. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $64K 100,581 shares at $0.6400 6% of stake
    Traded May 5–7 Filed May 7
    ↗
  12. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $198K 274,619 shares at $0.7200 14% of stake
    Traded Apr 30–May 4 Filed May 4
    ↗
  13. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $155K 205,911 shares at $0.7500 9.5% of stake
    Traded Apr 27–29 Filed Apr 29
    ↗
  14. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $21K 38,782 shares at $0.5400 1.8% of stake
    Traded Jan 16 Filed Jan 20
    ↗
  15. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $62K 111,227 shares at $0.5600 4.8% of stake
    Traded Jan 13–15 Filed Jan 15
    ↗
  16. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $54K 91,374 shares at $0.5900 3.8% of stake
    Traded Jan 8–12 Filed Jan 12
    ↗
  17. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $46K 71,054 shares at $0.6500 2.9% of stake
    Traded Jan 5–7 Filed Jan 7
    ↗
  18. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $48K 78,377 shares at $0.6200 3.1% of stake
    Traded Dec 30, 2025–Jan 2 Filed Jan 2
    ↗
  19. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $185K 291,283 shares at $0.6400 10% of stake
    Traded Dec 22–29 Filed Dec 29, 2025
    ↗
  20. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $52K 48,171 shares at $1.08 1.7% of stake
    Traded Dec 15–17 Filed Dec 17, 2025
    ↗
  21. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $89K 82,971 shares at $1.07 2.8% of stake
    Traded Dec 10–12 Filed Dec 12, 2025
    ↗
  22. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $95K 95,179 shares at $1.00 3.1% of stake
    Traded Dec 5–9 Filed Dec 9, 2025
    ↗
  23. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $118K 128,185 shares at $0.9200 4% of stake
    Traded Dec 2–4 Filed Dec 4, 2025
    ↗
  24. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $88K 91,088 shares at $0.9600 2.8% of stake
    Traded Nov 26, 2025–Dec 1, 2025 Filed Dec 1, 2025
    ↗
  25. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $115K 125,576 shares at $0.9200 3.7% of stake
    Traded Nov 21–25 Filed Nov 25, 2025
    ↗
  26. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $95K 102,753 shares at $0.9200 2.9% of stake
    Traded Nov 18–20 Filed Nov 20, 2025
    ↗
  27. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $129K 134,553 shares at $0.9600 3.7% of stake
    Traded Nov 13–17 Filed Nov 17, 2025
    ↗
  28. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $155K 137,041 shares at $1.13 3.6% of stake
    Traded Nov 7–12 Filed Nov 12, 2025
    ↗
  29. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $190K 155,885 shares at $1.22 4% of stake
    Traded Nov 4–6 Filed Nov 6, 2025
    ↗
  30. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $251K 189,356 shares at $1.33 4.6% of stake
    Traded Oct 30, 2025–Nov 3, 2025 Filed Nov 3, 2025
    ↗
  31. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $286K 177,145 shares at $1.62 4.1% of stake
    Traded Oct 27–29 Filed Oct 29, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,841 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.